Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

What happened: Regeneron reported longer-term Phase 3 C-POST data at ESMO 2026 showing adjuvant Libtayo (cemiplimab) improved overall survival in high-risk cutaneous squamous cell carcinoma after surgery and radiation. Key numbers: Median follow-up 44 months. Risk of death reduced 37% (HR 0.63; 95% CI 0.36-1.11), versus 22% at 30 months and 14% at 24 months. Why it matters: The emerging survival benefit despite high crossover supports treating high-risk patients with Libtayo after surgery and radiation rather than waiting for recurrence, per the lead investigator. Market: -1.7% today ($805.02), +4.0% YTD, 0.7x vol — as of 23:45 UTC

Regeneron reported longer-term Phase 3 C-POST data at ESMO 2026 showing adjuvant Libtayo (cemiplimab) improved overall survival in high-risk cutaneous squamous cell carcinoma after surgery and radiation.

The emerging survival benefit despite high crossover supports treating high-risk patients with Libtayo after surgery and radiation rather than waiting for recurrence, per the lead investigator. Market: -1.7% today ($805.02), +4.0% YTD, 0.7x vol — as of 23:45 UTC